Using varenicline in combination with electronic nicotine delivery systems (ENDS).

Autor: Rose JE; Rose Research Center, LLC, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: jed.rose@roseresearchcenter.com., Behm FM; Rose Research Center, LLC, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: Frederique.behm@roseresearchcenter.com., Willette PN; Rose Research Center, LLC, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: Perry.willette@roseresearchcenter.com., Botts TL; Rose Research Center, LLC, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: Tanaia.botts@roseresearchcenter.com., Botts DR; Rose Research Center, LLC, 7240 ACC Blvd, Raleigh, NC 27617, USA. Electronic address: David.botts@roseresearchcenter.com.
Jazyk: angličtina
Zdroj: Drug and alcohol dependence [Drug Alcohol Depend] 2023 Oct 01; Vol. 251, pp. 110916. Date of Electronic Publication: 2023 Aug 07.
DOI: 10.1016/j.drugalcdep.2023.110916
Abstrakt: Background: Varenicline is efficacious for smoking cessation, but a return to smokingusually occurs after treatment ends. Electronic nicotine delivery systems (ENDS) may enhance smoking reduction and cessation by providing a behavioral substitute for smoking and may deter smoking in the long term if an individual's nicotine dependence can be transferred to ENDS. The goal of this study was to evaluate varenicline in conjunction with ENDS to promote switching to ENDS.
Methods: Twenty-five individuals who smoked cigarettes, interested in switching but not seeking cessation treatment, received ENDS for 13 weeks; during weeks 2-13 they received varenicline. Assessments included self-reported cigarette and ENDS use, expired air carbon monoxide (CO), reward ratings, tolerability/side effects, and dependence measures.
Results: Cigarette smoking decreased from 15.6 cigarettes/day (SD=5.6) at baseline to 2.8 cigarettes/day (SD=5.1) at week 13 (paired t(22)=10.24, p<0.0001). 28% of participants were confirmed to be abstinent in the last 4 weeks of treatment. ENDS use remained relatively constant, averaging 11.8 occasions per day (SD=10.6). Cigarette dependence (assessed by time to first use of the day) decreased after introduction of ENDS (paired t(23) = -3.27, p=0.003), and again after the first week of full-dose varenicline (paired t(23) = -4.27, p=0.0003). Dependence on ENDS did not change, starting out lower than cigarettes (paired t(21) = 5.52, p<0.0001), but ending higher (paired t(22) = 2.94, p=0.008). Smoking satisfaction declined markedly, while satisfaction for ENDS remained relatively constant. Treatment tolerability and adherence were high.
Conclusions: ENDS in combination with varenicline shows promise as a means to reduce dependence on cigarettes and facilitate switching from cigarettes to ENDS.
Competing Interests: Declaration of Competing Interest JER and FMB disclose research support from Foundation for a Smoke-Free World, Philip Morris International, Altria, and JUUL Labs regarding research on noncombustible products with the potential to reduce exposure to toxic constituents of cigarette smoke. JER and FMB also have received research funding on the evaluation of pharmacological agents for smoking cessation treatment from Embera Neurotherapeutics, Inc., and Otsuka Pharmaceutical. JER and FMB have received consulting payments and research support from Revive Pharmaceuticals regarding a study of a sublingual nicotine tablet, and consulting and patent purchase agreement (last payment >10 years ago) with Philip Morris International on noncombustible nicotine delivery systems. TLB, DRB and PNW disclose research support from Foundation for a Smoke-Free World, Philip Morris International, Altria, Embera Neurotherapeutics, Inc., Otsuka Pharmaceutical, and JUUL Labs.
(Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: